

Arş. Gör. Dr. Kayhan ERTÜRK

Kişisel Bilgiler

E-posta: kayhan.erturk@istanbul.edu.tr

Eğitim Bilgileri

Tıpta Uzmanlık, İstanbul Üniversitesi, T. C. Sağlık Bakanlığı Bakırköy Dr. Sadi Konuk Eğitim Ve Araştırma Hastanesi, İç Hastalıkları, Türkiye 2009 - 2013

Tıpta Uzmanlık, İstanbul Üniversitesi, T.C. Sağlık Bakanlığı Şişli Etfal Eğitim Ve Araştırma Hastanesi, Aile Hekimliği, Türkiye 1997 - 2001

Lisans, İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, Türkiye 1989 - 1995

Yaptığı Tezler

Tıpta Uzmanlık, Akut miyokard infarktüsü geçiren kadınların eşlerinde koroner risk faktörleri, İstanbul Üniversitesi, T.C. Sağlık Bakanlığı Şişli Etfal Eğitim Ve Araştırma Hastanesi, Aile Hekimliği, 2001

Araştırma Alanları

Tıp, Sağlık Bilimleri, Dahili Tıp Bilimleri, İç Hastalıkları, Onkoloji

Akademik Unvanlar / Görevler

Araştırma Görevlisi Dr., İstanbul Üniversitesi, T.C. Sağlık Bakanlığı İstanbul Bakırköy Dr. Sadi Konuk Eğitim Ve Araştırma Hastanesi, İç Hastalıkları, 2009 - 2013

Araştırma Görevlisi Dr., İstanbul Üniversitesi, T.C. Sağlık Bakanlığı Şişli Etfal Eğitim Ve Araştırma Hastanesi, Aile Hekimliği, 1997 - 2001

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

- I. **Using Google as a Source of Information About Breast Cancer**
Tas F., Erturk K.
INDIAN JOURNAL OF SURGERY, cilt.85, sa.2, ss.473-475, 2023 (SCI-Expanded)
- II. **Unknown Primary Metastatic Melanoma Presented with Extensive Subcutaneous Masses and Lymph Node Enlargements**
Tas F., Erturk K.
INDIAN JOURNAL OF SURGERY, cilt.84, ss.579-580, 2022 (SCI-Expanded)
- III. **Larger Tumors Are Associated with Poorer Prognostic Factors in Cutaneous Melanoma**
Tas F., Erturk K.
INDIAN JOURNAL OF SURGERY, cilt.84, sa.3, ss.591-594, 2022 (SCI-Expanded)
- IV. **Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study**
Tacar S. Y., Selcukbiricik F., Yilmaz M., Erturk K., Sarici A. M., Gulturk I., Ayhan M., Tural D.

MELANOMA RESEARCH, cilt.31, sa.5, ss.449-455, 2021 (SCI-Expanded)

- V. **Cutaneous melanoma in vicenarians: Patients in their twenties and older patients show similar clinical behaviors and survival rates**
Tas F., Erturk K.
JOURNAL OF COSMETIC DERMATOLOGY, cilt.19, ss.2692-2696, 2020 (SCI-Expanded)
- VI. **Number of Excised Lymph Nodes Has No Impact on Relapse and Survival in Patients With Stage III Melanoma**
Tas F., Erturk K.
ANNALS OF PLASTIC SURGERY, cilt.83, sa.4, ss.455-458, 2019 (SCI-Expanded)
- VII. **Serum nectin-2 and nectin-4 are diagnostic in lung cancer: which is superior?**
Erturk K., Karaman S., Dagoglu N., Serilmez M., Duranyildiz D., Tas F.
WIENER KLINISCHE WOCHENSCHRIFT, sa.17-18, ss.419-426, 2019 (SCI-Expanded)
- VIII. **BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha**
Tas F., Erturk K.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, cilt.84, sa.3, ss.521-526, 2019 (SCI-Expanded)
- IX. **The course of stage III melanoma in accordance with the severity of node involvement**
Tas F., Erturk K.
CURRENT MEDICAL RESEARCH AND OPINION, cilt.35, sa.10, ss.1819-1824, 2019 (SCI-Expanded)
- X. **Lymph node ratio has impact on relapse and outcome in patients with stage III melanoma**
Tas F., Erturk K.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, cilt.24, sa.6, ss.721-726, 2019 (SCI-Expanded)
- XI. **Early and late relapses of cutaneous melanoma patients**
Tas F., Erturk K.
POSTGRADUATE MEDICINE, cilt.131, sa.3, ss.207-211, 2019 (SCI-Expanded)
- XII. **Cheek Cutaneous Melanomas A Review of 98 Cases**
Tas F., Erturk K.
ANNALS OF PLASTIC SURGERY, cilt.82, sa.4, ss.407-410, 2019 (SCI-Expanded)
- XIII. **Palpebral cutaneous melanomas: a review of 17 cases from a tertiary center**
Tas F., Erturk K.
INTERNATIONAL JOURNAL OF DERMATOLOGY, cilt.58, sa.1, ss.75-79, 2019 (SCI-Expanded)
- XIV. **Clinical significance of serum leptin level in patients with gastric cancer**
Tas F., Karabulut S., Erturk K., Duranyildiz D.
EUROPEAN CYTOKINE NETWORK, cilt.29, sa.2, ss.52-58, 2018 (SCI-Expanded)
- XV. **Anemia in Cutaneous Malignant Melanoma: Low Blood Hemoglobin Level is Associated with Nodal Involvement, Metastatic Disease, and Worse Survival**
Tas F., Erturk K.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, cilt.70, sa.2, ss.236-240, 2018 (SCI-Expanded)
- XVI. **Acral Lentiginous Melanoma Is Associated with Certain Poor Prognostic Histopathological Factors but May Not be Correlated with Nodal Involvement, Recurrence, and a Worse Survival**
Tas F., Erturk K.
PATHOBIOLOGY, cilt.85, sa.4, ss.227-231, 2018 (SCI-Expanded)
- XVII. **Digital clubbing as a first clinical presentation of pulmonary metastases in cutaneous melanoma**
Tas F., Erturk K.
POSTGRADUATE MEDICINE, cilt.130, sa.2, ss.278-279, 2018 (SCI-Expanded)
- XVIII. **Cutaneous Melanoma in Association With Ichthyosis Vulgaris**
Tas F., Erturk K., DEMİRKESEN C., Goktay F.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, cilt.39, sa.8, ss.630, 2017 (SCI-Expanded)
- XIX. **Scalp melanoma is associated with high mitotic rate and is a poor prognostic factor for recurrence and outcome**
Tas F., Erturk K.

- MELANOMA RESEARCH, cilt.27, sa.4, ss.387-390, 2017 (SCI-Expanded)
- XX. **Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors**
Tas F., Erturk K.
MELANOMA RESEARCH, cilt.27, sa.2, ss.134-139, 2017 (SCI-Expanded)
- XXI. **Histological lymphovascular invasion is associated with nodal involvement, recurrence, and survival in patients with cutaneous malignant melanoma**
Tas F., Erturk K.
INTERNATIONAL JOURNAL OF DERMATOLOGY, cilt.56, sa.2, ss.166-170, 2017 (SCI-Expanded)
- XXII. **Tumor Infiltrating Lymphocytes (TILs) May be Only an Independent Predictor of Nodal Involvement but not for Recurrence and Survival in Cutaneous Melanoma Patients**
Tas F., Erturk K.
CANCER INVESTIGATION, cilt.35, sa.8, ss.501-505, 2017 (SCI-Expanded)
- XXIII. **Clinical significance of serum claudin-1 levels in melanoma patients**
Tas F., Bilgin E., Erturk K., Duranyildiz D.
MELANOMA RESEARCH, cilt.26, sa.4, ss.377-381, 2016 (SCI-Expanded)
- XXIV. **Serum activated leukocyte cell adhesion molecule and intercellular adhesion molecule-1 in patients with gastric cancer: Can they be used as biomarkers?**
Erturk K., Tastekin D., Bilgin E., Serilmez M., Bozbey H. U., Sakar B.
BIOMEDICINE & PHARMACOTHERAPY, cilt.77, ss.86-91, 2016 (SCI-Expanded)
- XXV. **Is it solitary plasmacytoma or nonsecretory myeloma? A must-be-solved dilemma?**
Erturk K., Tastekin D., Gundogdu G., Tas F., Vatansever S.
BIOMEDICINE & PHARMACOTHERAPY, cilt.77, ss.27-29, 2016 (SCI-Expanded)
- XXVI. **Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer**
Erturk K., Tastekin D., Serilmez M., Bilgin E., Bozbey H. U., Vatansever S.
TUMOR BIOLOGY, cilt.37, sa.1, ss.405-412, 2016 (SCI-Expanded)
- XXVII. **Preoperative chemotherapy for T2 breast cancer is associated with improved surgical outcome**
Karanlık H., Özgür I., Cabioglu N., Sen F., Erturk K., Kilic B., Onder S., Deniz M., Yavuz E., Aydinler A.
EJSO, cilt.41, sa.9, ss.1226-1233, 2015 (SCI-Expanded)
- XXVIII. **The efficacy of Pistacia Terebinthus soap in the treatment of cetuximab-induced skin toxicity**
Tastekin D., Tambas M., KILIC K., Erturk K., ARSLAN D.
INVESTIGATIONAL NEW DRUGS, cilt.32, sa.6, ss.1295-1300, 2014 (SCI-Expanded)

Diğer Dergilerde Yayınlanan Makaleler

- I. **Widespread finger skin metastases of melanoma**
Tas F., Erturk K.
CLINICAL CASE REPORTS, cilt.6, sa.2, ss.448-449, 2018 (ESCI)
- II. **Effect of biology on the outcome of female melanoma patients**
Erturk K., Tas F.
MOLECULAR AND CLINICAL ONCOLOGY, cilt.7, sa.6, ss.1093-1100, 2017 (ESCI)
- III. **Elevated erythrocyte sedimentation rate is associated with metastatic disease and worse survival in patients with cutaneous malignant melanoma**
Tas F., Erturk K.
MOLECULAR AND CLINICAL ONCOLOGY, cilt.7, sa.6, ss.1142-1146, 2017 (ESCI)
- IV. **Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival**
Tas F., Erturk K.
MOLECULAR AND CLINICAL ONCOLOGY, cilt.7, sa.6, ss.1083-1088, 2017 (ESCI)

- V. **Clinical significance of serum Protease-Activated Receptor-1 (PAR-1) levels in patients with cutaneous melanoma**
Tas F., Bilgin E., Karabulut S., Erturk K., Duranyildiz D.
BBA CLINICAL, cilt.5, ss.166-169, 2016 (ESCI)
- VI. **Serum IGF-1 and IGFBP-3 levels as clinical markers for patients with lung cancer**
Tas F., Bilgin E., Tastekin D., Erturk K., Duranyildiz D.
BIOMEDICAL REPORTS, cilt.4, sa.5, ss.609-614, 2016 (ESCI)
- VII. **Clinical significance of serum laminin levels in patients with lung cancer**
Tas F., Bilgin E., Tastekin D., Erturk K., Duranyildiz D.
BIOMEDICAL REPORTS, cilt.4, sa.4, ss.485-488, 2016 (ESCI)
- VIII. **Pankreas adenokarsinomlu hastalarda serum transforme edici büyüme factor beta 1 TGF B1 düzeyleri**
KARABULUT S., KARABULUT M., AFŞAR USUL Ç., ALIŞ H., DAĞOĞLU N., AKARSU C., ERTÜRK K., BİLGİN E., TAŞ F.
İstanbul Tıp Fakültesi Dergisi, cilt.79, sa.1, ss.9-15, 2016 (Hakemli Dergi)
- IX. **SERUM TRANSFORMING GROWTH FACTOR BETA 1 (TGF-B1) LEVELS IN PANCREATIC ADENOCARCINOMA PATIENTS**
Karabulut S., Karabulut M., Usul Afsar C., Alis H., Dagoglu N., Akarsu C., Erturk K., Bilgin E., Tas F.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGİSİ, sa.1, ss.9-15, 2016 (ESCI)

Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar

- I. **Mide Kanserinde Serum Interleukin-29, Interleukin-32 ve Tumor Necrosis Factor Alpha'nın Klinik Önemi**
ERTÜRK K., TAŞTEKİN D., SERİLMEZ M., BİLGİN DOĞRU E., H. U., VATANSEVER S.
3. Ulusal İmmüno-Onkoloji ve Hedefe Yönelik Kanser Tedavileri Kongresi, Antalya, Türkiye, 11 - 15 Mayıs 2016, ss.1
- II. **Diagnostic and prognostic roles of serum interleukin-32 (IL-32) levels in patients with pancreatic adenocarcinoma.**
KARABULUT S., Afsar C. U., Yasasever V., Karabulut M., Erturk K., Alis H., Gunaldi M., Peker K. D., Dagoglu N., TAŞ F.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34
- III. **The role of adhesion molecules in hepatocellular carcinoma**
Tastekin D., DIKİLİTAS M., HARPUTLUOĞLU H., Erturk K., CELEBİ K., Sen F., BOZBEY H. U.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33
- IV. **Do serum nectin-2 levels have a prognostic effect in patients with colorectal cancer?**
Basaran M., KARABULUT S., KARABULUT M., GUNALDI M., ALIS H., Erturk K., Vatansever S., Sakar B., Aykan N. F.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33
- V. **Clinical significance of serum claudin-7 levels in patients with colorectal cancer.**
Aydogan F., Karabulut M., Alis H., Karabulut S., Celebi K., Bozbey H. U., Erturk K., Vatansever S., Aykan N. F.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33

Desteklenen Projeler

KIZIR A., SERİLMEZ M., BİLGİN DOĞRU E., TILGEN YASASEVER C., ERTÜRK K., Yükseköğretim Kurumları Destekli Proje,

Metrikler

Yayın: 42

Atıf (WoS): 247

Atıf (Scopus): 236

H-İndeks (WoS): 10

H-İndeks (Scopus): 9